MedTrace Logo

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

NCT03248037 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-02-12

Study results available
· View outcomes & findings →

Summary

Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.

Conditions

  • Fuchs' Endothelial Dystrophy
  • Bullous Keratopathy

Interventions

DRUG

Netarsudil

netarsudil opthalmic solution 0.02%

DRUG

Placebo

Placebo eye drops

Sponsors & Collaborators

  • Cornea Research Foundation of America

    lead OTHER

Principal Investigators

  • Francis W Price, Jr, MD · Price Vision Group

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-05
Primary Completion
2019-07-09
Completion
2019-07-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03248037 on ClinicalTrials.gov